InfanDx
Cologne
About InfanDx
InfanDx AG aims to contribute to this goal by developing a new generation of diagnostic tests for the care of neonates. Primary focus is the early identification of newborns suffering from critical oxygen supply deficit during birth (Asphyxia), a major cause for brain injury often followed by life long disabilitation. Nowadays, treatment that reduces morbidity is available. Unfortunately, it requires very early application after birth. Currently no test system is available that meets this crucial demand. InfanDx closes this diagnostic gap by carrying such test system through clinical development until it is available for routine use in the hospital.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $5.9M
- Last round: Series Unknown (Apr 2019)
- Website: infandx.de
- Phone: +49 (0) 221 30089783
Industries & Categories
Health Care, Health Diagnostics
Canonical: https://fsome.com/organization/infandx-82497 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.